Cabotegravir Injection [Apretude]
Phase 3
Cabotegravir Injection [Apretude] is one of 4 therapeutic programs targeting Pre-Exposure Prophylaxis (PrEP). It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
3 competitors in Pre-Exposure Prophylaxis (prep)
#DrugCompanyPhaseTrials
1Cabenuva
GSKApproved
Sunlenca
GileadPhase 2
Cabotegravir Injection [Apretude]
BBeth Israel Deaconess Medical Center
Phase 3
Emtricitabine/tenofovir Alafenamide
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]